Pitcairn Co. Cuts Stake in Haleon PLC Sponsored ADR $HLN

Pitcairn Co. lessened its holdings in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 36.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 178,503 shares of the company’s stock after selling 100,878 shares during the quarter. Pitcairn Co.’s holdings in Haleon were worth $1,601,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Golden State Wealth Management LLC lifted its holdings in shares of Haleon by 107.6% in the second quarter. Golden State Wealth Management LLC now owns 2,721 shares of the company’s stock worth $28,000 after buying an additional 1,410 shares in the last quarter. SOA Wealth Advisors LLC. grew its stake in Haleon by 60.5% during the third quarter. SOA Wealth Advisors LLC. now owns 3,105 shares of the company’s stock valued at $28,000 after acquiring an additional 1,170 shares in the last quarter. Citizens National Bank Trust Department grew its stake in Haleon by 167.4% during the third quarter. Citizens National Bank Trust Department now owns 3,276 shares of the company’s stock valued at $29,000 after acquiring an additional 2,051 shares in the last quarter. Atlantic Union Bankshares Corp increased its holdings in Haleon by 293.7% in the 3rd quarter. Atlantic Union Bankshares Corp now owns 3,697 shares of the company’s stock valued at $33,000 after acquiring an additional 2,758 shares during the last quarter. Finally, Geneos Wealth Management Inc. lifted its stake in Haleon by 33.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after purchasing an additional 1,203 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. HSBC upgraded Haleon from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 21st. Morgan Stanley reaffirmed an “overweight” rating on shares of Haleon in a research note on Monday, December 15th. Jefferies Financial Group reiterated a “buy” rating on shares of Haleon in a research report on Tuesday, January 20th. Deutsche Bank Aktiengesellschaft lowered shares of Haleon from a “hold” rating to a “sell” rating in a report on Monday, January 12th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $12.33.

Haleon Price Performance

NYSE:HLN opened at $10.28 on Friday. The firm has a market capitalization of $45.78 billion, a price-to-earnings ratio of 26.36 and a beta of 0.18. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71. The business has a 50 day simple moving average of $10.50 and a 200-day simple moving average of $9.84. Haleon PLC Sponsored ADR has a 1 year low of $8.71 and a 1 year high of $11.42.

Haleon Announces Dividend

The company also recently disclosed a dividend, which will be paid on Thursday, May 14th. Shareholders of record on Friday, April 10th will be paid a dividend of $0.1307 per share. This represents a yield of 251.0%. The ex-dividend date of this dividend is Friday, April 10th. Haleon’s payout ratio is presently 28.21%.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.